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ABSTRACT
Background: Elevated body iron stores have been suggested to
be a risk factor for ischemic heart disease.
Objective: We examined whether elevated serum ferritin con-
centrations, other indicators of iron status, and dietary iron
affected the incidence of myocardial infarction (MI) in an
elderly population.
Design: A nested, case-control study of 60 patients who had
their first MI and 112 age- and sex-matched control subjects
embedded in the population-based cohort of the Rotterdam
Study.
Results: The age- and sex-adjusted risk of MI for subjects with
serum ferritin concentrations ‡ 200 mg/L was 1.82 (95% CI:
0.90, 3.69; P = 0.096). The odds ratio (OR) was 1.26 (95% CI:
0.98, 1.64; P = 0.078) for the highest tertile of serum ferritin and
was only slightly altered in a multivariate model. Risk of MI
associated with the highest tertile of ferritin was most evident in
current or former smokers (OR: 1.68; 95% CI: 1.17, 2.47; P for
trend = 0.008) and in subjects with hypercholesterolemia (OR:
1.43; 95% CI: 0.99, 2.11; P for trend = 0.056) or diabetes (OR:
2.41; 95% CI: 1.12, 7.67; P for trend = 0.027). No association
with risk of MI was observed for tertiles of serum iron, serum
transferrin, or total dietary iron. For dietary heme iron, risk of
MI was significantly increased in a multivariate model in which
dietary energy, fat, saturated fat, and cholesterol were adjusted
for (OR: 4.01; 95% CI: 1.17, 15.87; P for trend = 0.031).
Conclusion: In the presence of other risk factors, serum ferritin
may adversely affect ischemic heart disease risk in the elderly.
Am J Clin Nutr 1999;69:1231–6.
KEY WORDS Serum ferritin, iron status, myocardial
infarction, ischemic heart disease, Rotterdam Study, elderly
INTRODUCTION
Free iron—a catalyst of the production of free radicals—has
been implicated in ischemic myocardial damage and lipid perox-
idation. Hypotheses as to how free iron may accelerate the pro-
gression of atherosclerosis or contribute to myocardial injury
after an ischemic event have been generated from basic research.
Direct evidence that high stored iron concentrations or high iron
intakes increase the incidence of ischemic heart disease in
humans, however, is limited. The strongest supporting evidence
stems from a cohort study of eastern Finnish men, in whom high
concentrations of serum ferritin and dietary iron were positively
associated with the incidence of myocardial infarction (1). Fur-
thermore, serum ferritin was observed to be one of the strongest
indicators of the presence and progression of carotid artery dis-
ease (2, 3). Blood donation, which depletes iron stores in the
donors, was associated with reduced risk of myocardial infarction
(4) and cardiovascular disease (5). However, most subsequent
studies investigating whether iron status or dietary iron intake are
associated with increased risk of myocardial infarction or
ischemic heart disease have not provided consistent results
(6–14). Using a nested, case-control approach, we studied
whether serum ferritin and other indicators of iron status were
associated with the incidence of myocardial infarction in the pop-
ulation of the Rotterdam Study.
SUBJECTS AND METHODS
Study population and case ascertainment
The Rotterdam Study is a community-based, prospective cohort
study of 7983 persons (response rate 78%) aged ‡ 55 y living in
Ommoord, an urban district in Rotterdam, Netherlands. The aim
of the study was to investigate the incidence of and the risk fac-
tors for chronic and disabling cardiovascular, neurodegenerative,
locomotor, and ophthalmic diseases as described elsewhere (15).
The study was approved by the Medical Ethics Committee of
Erasmus University and written, informed consent was obtained
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from all participants. The follow-up for ischemic heart disease
started after the baseline survey in 1990. Until April 1996 (mean:
4 y), follow-up information was available for 94% of the cohort.
With respect to the vital status of participants, information was
obtained at regular intervals from the municipal health service in
Rotterdam. Information on fatal and nonfatal endpoints was
obtained from the general practitioners (GPs) working in the
study district of Ommoord. All possible events reported by the
GPs were verified by research physicians from the Rotterdam
Study through records of the participating GPs and medical spe-
cialists. Causes and circumstances of death were obtained from
the GP and from hospital-discharge records in cases of admit-
tance or referral, shortly after death was reported by the munici-
pal health service or the GP. Classification of fatal and nonfatal
events was based on the International Classification of Diseases
(ICD), 10th revision (16). In the present analysis, cases of first
myocardial infarction (ICD-10:I21-I24) were used. All events
were classified independently by 2 research physicians. If there
was disagreement about case status, a consensus was reached in a
special session. Finally, all these events were verified by a car-
diovascular disease expert. In case of discrepancies, the judgment
by this expert was considered definite.
A nested, case-control approach was used to examine the asso-
ciation between serum ferritin and risk of fatal and nonfatal
myocardial infarction. For every subject with a first myocardial
infarction during follow-up (n = 202), a control subject without a
cardiac endpoint was selected. Age strata (5-y interval) and sex
were used as matching variables. Frozen serum samples, stored at
220 8C for determination of serum ferritin, were available for 255
subjects (111 case subjects with myocardial infarction and 144
control subjects). Blood samples were not available for all cases
and control subjects allocated to this study because multiple
blood samples were used in the Rotterdam Study. Subjects with
C-reactive protein concentrations >6 mg/L, with missing C-reac-
tive protein data, or an erythrocyte sedimentation rate 
>20 mm/h (n = 25 cases and 15 control subjects), indicating the
presence of inflammation or infection that could potentially lead
to elevated ferritin concentrations, were excluded from analysis.
After exclusion of subjects with a verified history of myocardial
infarction, 172 subjects [60 cases (35 nonfatal and 25 fatal) and
112 control subjects] remained for analysis of serum ferritin and
risk of myocardial infarction.
Baseline measurements
Information on current health status, medical history, drug
use, education, income, and smoking behavior was obtained with
use of a computerized questionnaire during a home interview.
Height and weight were measured and body mass index [wt (in
kg)/ht2 (in m)] was calculated as a measure of obesity. Sitting
blood pressure was measured on the right upper arm with a ran-
dom-zero sphygmomanometer. The average of 2 measurements
was used in the analysis. A venipuncture was performed and
hematologic indexes were obtained by standard clinical labora-
tory procedures. Serum total and HDL-cholesterol concentra-
tions were determined at baseline by using an automated enzy-
matic procedure. Serum samples were collected from the case
and control subjects simultaneously at baseline and frozen at
220 8C until used to determine concentrations of ferritin, iron,
transferrin, ceruloplasmin, and C-reactive protein. Sera from
case and control subjects were analyzed in the same run. Serum
ferritin concentrations were determined by enzyme-linked
immunosorbent assay (Boehringer Mannheim, Mannheim, Ger-
many). The CVs were 2.8%, 4.0%, and 10.4% for ferritin con-
centrations of 389, 139, and 27 mg/L, respectively. Serum trans-
ferrin and C-reactive protein were measured by kinetic
nephelometry with a Beckman-Array system (Munich, Ger-
many) and serum iron was determined by photometry with an
EPOS Chemistry Analyzer (Boehringer Mannheim). CVs were
4%, 2%, 4.6%, and 3.8% for transferrin, iron, ceruloplasmin, and
C-reactive protein, respectively.
Dietary assessment
The semiquantitative food-frequency questionnaire (SFFQ)
completed during baseline aimed at assessing habitual food
intake during the past year and included 170 food items in 13
food groups and questions about dietary habits, supplementa-
tion, and prescribed diets. SFFQ data were converted to nutrient
intake by using the computerized Dutch food-composition table
(17). Heme iron was estimated to account for 40% of the total
iron intake from meat, poultry, and fish (18). Data for b-carotene 
and tocopherol were updated by using an additional database
from the Netherlands Institute of Public Health and Environ-
mental Protection (YCJ Volleburgt, EJM Feskens, unpublished
observations, 1993). Nutrient intakes from nutritional supple-
ments were not considered because brand labels, doses, and
durations were not recorded with sufficient accuracy. The valid-
ity of the SFFQ assessed in a subsample of 80 men and women
aged 55–75 y. Nutrient intakes estimated from the SFFQ were
compared with estimated nutrient intakes from 15 d of food
records collected over 1 y (19). The ability of the SFFQ to ade-
quately rank subjects according to their dietary intake was
shown by Pearson’s correlation coefficients (0.5–0.9 for crude
data) and a high degree of classification into the same or adja-
cent quintile (75.8% for crude data). The Pearson’s correlation
coefficient between food records and the SFFQ for iron intake
was 0.67.
Data analysis
Associations between serum ferritin and risk factors for
ischemic heart disease were investigated by using Pearson’s cor-
relation coefficients; those for categorical variables were inves-
tigated by using the chi-square test. Analysis of variance was
used to test for differences in baseline characteristics between
cases and control subjects. All analyses were adjusted for age
and sex. Serum ferritin was categorized as being < or ‡ 200 mg/L
and the risk of myocardial infarction was investigated by multi-
variate logistic regression. Estimation of CIs was based on the
likelihood ratio. To evaluate whether there was a graded associ-
ation between serum ferritin concentrations and risk of myocar-
dial infarction, analyses were performed for tertiles of serum
ferritin. Analyses were initially adjusted for age and sex and
subsequently for body mass index, pack-years of smoking (ie,
the number of packs of cigarettes smoked per day times the
number of years smoked), equivalent household income (5 cat-
egories), and alcohol intake (5 categories). To evaluate whether
smoking status, hypertension, hypercholesterolemia, or diabetes
modified the association between serum ferritin and myocardial
infarction, stratified analyses were conducted. In addition, the
association between risk of myocardial infarction and other
measures of iron status (serum iron and transferrin) and dietary
iron intake (total iron and heme iron) was evaluated. For dietary
intakes of total and heme iron, the multivariate model was fur-
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ther adjusted for categories of energy, fat, saturated fat, and cho-
lesterol. Associations are expressed as odds ratios (ORs) with
95% CIs. Two-sided P values were calculated. Statistical analy-
ses were performed by using SAS statistical software (version
6.11; SAS Institute, Cary, NC).
RESULTS
Serum ferritin concentrations in the case-control population
ranged from 10 to 1221 mg/L and averaged 47, 119, and 
309 mg/L per tertile. Median concentrations of serum ferritin were 
129 mg/L for men and 101 mg/L for women. Serum ferritin was
significantly inversely associated with serum transferrin
(r = 20.28, P = 0.002) and was directly associated with serum
iron and alcohol intake. A weak association (r = 0.14, P = 0.17)
was noted for serum ferritin and heme iron intake. The distribu-
tion of serum ferritin for cases and control subjects indicated a
shift toward higher serum ferritin concentrations in patients with
myocardial infarction (Figure 1). Correspondingly, more patients
with myocardial infarction (33.3%) than control subjects
(21.4%) had concentrations above the cutoff of 200 mg fer-
ritin/L. Cases and control subjects differed significantly in heme
iron intake (Table 1).
When adjusted for age and sex, subjects with a serum ferritin
concentration ‡ 200 mg/L tended to have a risk of 1.82 (95% CI:
0.90, 3.69; P = 0.096) for myocardial infarction compared with
those with serum ferritin concentrations < 200 mg/L. Further
adjustment for body mass index, pack-years of smoking, income,
and alcohol intake only marginally altered the risk of myocardial
infarction (OR: 1.81; 95% CI: 0.88, 3.74; P = 0.108). To evalu-
ate whether there was a graded association between serum fer-
ritin concentrations and risk of myocardial infarction, serum fer-
ritin tertiles were examined. Age- and sex-adjusted ORs for the
highest compared with the lowest tertile were 1.26 (95% CI:
0.98, 1.64; P for trend = 0.070) and 1.28 (95% CI: 0.98, 1.67; 
P for trend = 0.066), respectively, in the multivariate adjusted
model (Table 2). Inclusion of subjects with an elevated C-reactive
protein or erythrocyte sedimentation rate gave smaller estimates
for subjects with ferritin concentrations ‡ 200 mg/L (age- and
sex-adjusted OR: 1.46; 95% CI: 0.75, 2.80 ), indicating misclas-
sification of iron status when subjects with signs of inflamma-
tion were not excluded from the analyses. No association with
risk of myocardial infarction was observed for tertiles of serum
iron, serum transferrin, or total dietary iron (Table 2). For dietary
heme iron, a significantly increased risk of myocardial infarction
was observed for the highest compared with the lowest tertile of
heme iron intake in an age- and sex-adjusted model (OR: 2.79;
95% CI: 1.01, 8.13; P for trend = 0.047). Multivariate adjust-
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FIGURE 1. Serum ferritin concentrations in cases and control subjects with myocardial infarction.
TABLE 1
Baseline characteristics of case subjects with myocardial infarction and
control subjects
Case subjects Control subjects
Variables (n = 60) (n = 112)
Men (%) 44.6 45.0
Age (y) 75.9 – 8.51 76.4 – 8.9
Body mass index (kg/m2) 26.2 – 2.8 26.0 – 3.5
Waist-to-hip ratio 0.93 – 0.09 0.92 – 0.08
Diastolic blood pressure (mm Hg) 75 – 12 74 – 12
Systolic blood pressure (mm Hg) 148 – 21 143 – 23
Ferritin (mg/L) 183 – 168 144 – 142
Transferrin (g/L) 2.52 – 0.45 2.59 – 0.42
Serum iron (mmol/L) 16.4 – 5.0 16.9 – 5.2
Serum cholesterol (mmol/L) 6.80 – 1.22 6.53 – 1.33
Serum HDL cholesterol (mmol/L) 1.26 – 0.28 1.27 – 0.32
Obesity (%) 10.0 13.4
Hypertension (%)2 36.7 32.1
Hypercholesterolemia (%)3 55.0 44.6
Diabetes (%) 20.3 20.6
Current smokers (%) 18.3 16.1
High alcohol intake4 3.3 5.4
Dietary iron (mg/d)5 12.1 – 2.7 12.5 – 3.5
Dietary heme iron (mg/d)5 1.14 – 0.466 0.95 – 0.36
1 x– – SD.
2 Defined as a systolic blood pressure >160 mm Hg, a diastolic blood
pressure >95 mm HG, or use of antihypertensive medication.
3 Serum cholesterol > 6.5 mmol/L.
4 Alcohol intake >20 g/d for women and >30 g/d for men.
5 Dietary data available for 37 case subjects with myocardial infarction
and 66 control subjects.
6 Significantly different from control subjects, P = 0.016.
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ment, including dietary variables that could potentially confound
the association between heme iron and myocardial infarction
resulted in an OR of 4.01 (95% CI: 1.17, 15.87; P for trend = 0.031).
Further adjustment by dietary antioxidants (b-carotene, vitamin C,
and vitamin E) did not materially alter the risk estimate.
Stratification by smoking status, hypercholesterolemia, and
diabetes showed modification of the association between serum
ferritin and myocardial infarction (Table 3). Risk of myocardial
infarction was more pronounced in hypercholesterolemia (OR:
1.43; 95% CI: 0.99, 2.11; P for trend = 0.056 for the highest
compared with the lowest tertile of serum ferritin) and diabetes
(OR: 2.50; 95% CI: 1.15, 8.05; P for trend = 0.020). Both cur-
rent and former smoking considerably increased the risk of
myocardial infarction in association with elevated serum ferritin
concentrations.
DISCUSSION
In this study of an elderly Dutch population, elevated serum
ferritin concentrations were associated with increased risk of
myocardial infarction. It was most pronounced in current and
former smokers and in those with diabetes. Serum iron, transfer-
rin, and dietary total iron were not associated with myocardial
infarction. High heme iron intake, however, was significantly
associated with increased myocardial infarction risk.
Studies investigating whether iron status can be considered a
cardiovascular risk factor presented conflicting results, as
reviewed recently (20, 21). This was not unexpected because none
of the indicators of iron status evaluated—hemoglobin, hemat-
ocrit, serum iron, transferrin, transferrin saturation, total iron bind-
ing capacity, or ferritin—accurately reflects body iron (22).
Because serum ferritin concentrations are directly proportional to
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TABLE 2
Odds ratios and 95% CIs for myocardial infarction (MI) according to tertiles of indicators of iron status
Tertiles
Variable 1 (Lowest)1 2 3 (Highest) P for trend
Serum ferritin
Case subjects with MI (n) 17 17 26 —
Control subjects (n) 41 40 31 —
Concentration (mg/L) <77 77–171 >171 —
Odds ratio (95% CI)
Adjusted for age and sex 1.00 1.01 (0.67, 1.51) 1.26 (0.98, 1.64) 0.070
Multivariate adjusted2 1.00 1.08 (0.71, 1.64) 1.28 (0.98, 1.67) 0.066
Serum iron
Case subjects with MI (n) 23 16 21 —
Control subjects (n) 35 42 35 —
Concentration (mmol/L) <14.1 14.1–18.9 > 18.9 —
Odds ratio (95% CI)
Adjusted for age and sex 1.00 0.75 (0.50, 1.11) 0.95 (0.72, 1.24) 0.699
Multivariate adjusted2 1.00 0.77 (0.51, 1.15) 0.97 (0.73, 1.28) 0.788
Serum transferrin
Case subjects with MI (n) 25 20 15 —
Control subjects (n) 49 31 32 —
Concentration (g/L) <2.5 2.5–2.7 >2.7 —
Odds ratio (95% CI)
Adjusted for age and sex 1.00 1.12 (0.77, 1.63) 0.97 (0.75, 1.26) 0.909
Multivariate adjusted2 1.00 1.15 (0.78, 1.68) 0.96 (0.73, 1.25) 0.624
Dietary iron3
Case subjects with MI (n) 12 14 11 —
Control subjects (n) 23 20 23 —
Intake (mg/d) <11.1 11.1–13.1 >13.1 —
Odds ratio (95% CI)
Adjusted for age and sex 1.00 1.73 (0.61, 5.09) 1.33 (0.43, 4.26) 0.641
Multivariate adjusted2 1.00 1.49 (0.50, 4.62) 1.35 (0.41, 4.62) 0.606
Multivariate adjusted4 1.00 2.12 (0.57, 8.45) 3.02 (0.50, 20.52) 0.274
Dietary heme iron3
Case subjects with MI (n) 9 12 16 —
Control subjects (n) 26 22 18 —
Intake (mg/d) <0.86 0.86–1.10 >1.10 —
Odds ratio (95% CI)
Adjusted for age and sex 1.00 1.68 (0.59, 4.96) 2.79 (1.01, 8.13) 0.047
Multivariate adjusted2 1.00 1.66 (0.56, 5.08) 2.75 (0.92, 8.64) 0.069
Multivariate adjusted4 1.00 1.85 (0.61, 5.91) 4.01 (1.17, 15.87) 0.031
1 Reference category.
2 Adjusted for age, sex, body mass index, pack-years of smoking, equivalent household income (5 categories), and alcohol intake (5 categories).
3 Dietary data available for 37 case subjects with myocardial infarction and 66 control subjects.
4 Adjusted for age, sex, body mass index, pack-years of smoking, equivalent household income (5 categories), alcohol intake (5 categories), and categories
of dietary energy, total fat, saturated fat, and cholesterol.
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intracellular ferritin concentrations, it is considered to be the best
clinical measure of body iron stores (22) and the most feasible to
use in epidemiologic studies (23). However, so far only a few stud-
ies evaluated serumferritin concentrations to examine whether
body iron stores are associated with cardiovascular disease. Serum
ferritin concentrations are known to increase in response to
inflammation. To circumvent a confounding effect of inflamma-
tion on serum ferritin concentrations, we excluded from analysis
subjects with C-reactive protein concentrations >6 mg/L or, if data
for C-reactive protein were missing, erythrocyte sedimentation
rates >20 mm/h.
Previous evidence of an association between increased risk of
myocardial infarction and elevated serum ferritin concentrations
came from the Kuopio Ischaemic Heart Disease Risk Factor
Study, which followed 1931 men for an average of 3 y (1). Men
with serum ferritin concentrations ‡ 200 mg/L had a 2.2-fold
(95% CI: 1.2, 4.0; P < 0.01) higher risk of myocardial infarction
than did men with lower serum ferritin concentrations after
adjustment for other risk factors. This association was stronger in
men with serum LDL concentrations ‡ 5.0 mmol/L ( ‡ 193 mg/dL).
Extended follow-up after a mean follow-up period of 5 y con-
firmed these previous findings (24). In 847 Austrian men and
women aged 40–79 y, Kiechl et al (2) examined the relation
between sonographically assessed carotid atherosclerosis and
body iron stores. Ferritin was observed to be one of the strongest
indicators of the presence of carotid artery disease (OR: 1.54 per
100 mg/L serum ferritin; P < 0.001) in men and women aged
40–59 y. Again, a synergistic effect between hypercholesterolemia
and serum ferritin concentrations was observed. Five-year follow-
up showed that serum ferritin was also a strong risk predictor of
overall progression of atherosclerosis and of incident cardiovas-
cular disease and death. Risk of atherosclerosis and cardiovascu-
lar disease was modified by serum LDL cholesterol. Changes in
iron stores during the follow-up period modified the risk of ath-
erosclerosis: a reduction was beneficial and further iron accumu-
lation was not (3). Further studies relating serum ferritin concen-
trations to carotid intima media thickness (25), presence of ather-
osclerosis (26), myocardial infarction (6, 7), or ischemic heart
disease (8, 27) did not support an association between body iron
stores and risk of cardiovascular disease. However, studies of the
effect of blood donation or phlebotomy, resulting in a consider-
able decrease in serum ferritin concentrations, on cardiovascular
disease risk support the finding of a decreased risk. Meyers et al
(5), who compared cardiovascular event rates between whole-
blood donors and nondonors, showed that blood donation was
associated with a reduced risk of cardiovascular events (crude
OR: 0.50; 95% CI: 0.38, 0.66) after 5–8 y of follow-up. The ben-
efit of donation was confined to nonsmoking males (adjusted OR:
0.67; 95% CI: 0.45, 0.99), limited to blood donation in the most
recent 3 y, and was greater in nonsmoking men with serum LDL-
cholesterol concentrations >4.14 mmol/L (160 mg/dL). Among
2682 Finnish men, blood donation was prospectively associated
with a reduction in risk of myocardial infarction of 86% (4).
However, likely self-selection by healthier persons to be blood
donors should be considered. Examination of the effect of phle-
botomy on the oxidation resistance of serum lipoproteins in 14
men with elevated serum ferritin concentrations showed signifi-
cantly decreased maximal oxidation and increased lag time to
start of oxidation (28).
We observed risk of myocardial infarction to be confined to
current and former smokers and to be more pronounced in sub-
jects with diabetes or serum cholesterol concentrations >6.5 mmol/L
(Table 3). The effects of iron stores on atherogenesis were more
pronounced in smokers (3) and synergistic effects between serum
ferritin and serum cholesterol or LDL cholesterol have been
reported as discussed above (1–3). These findings indicate that
high serum ferritin may increase the risk of ischemic heart dis-
ease in the presence of other risk factors that increase the forma-
tion of free radicals, thus accelerating atherogenesis via stimula-
tion of LDL oxidation (29, 30). Basic research has provided
strong evidence that LDL oxidation plays an important role in the
pathogenesis of atherosclerosis and cardiovascular disease. Oxi-
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TABLE 3
Odds ratio and 95% CIs for myocardial infarction (MI) for tertiles of serum ferritin1
Tertiles
Variable 1 (Lowest)2 2 3 (Highest) P for trend
Serum ferritin (mg/L) <77 77–171 >171
Smoking status3
Current (n = 11 MI, 18 C) 1.00 0.39 (0.07, 1.66) 2.62 (1.12, 9.10) 0.047
Former (n = 29 MI, 46 C) 1.00 1.63 (0.88, 3.13) 1.56 (1.01, 2.48) 0.046
Nonsmoker (n = 20 MI, 48 C) 1.00 0.80 (0.36, 1.70) 1.00 (0.65, 1.54) 0.975
Hypertension4
Present (n = 18 MI, 44 C) 1.00 0.96 (0.55, 1.66) 1.23 (0.88, 1.74) 0.219
Not present (n = 42 MI, 68 C) 1.00 1.02 (0.46, 2.31) 1.26 (0.76, 2.12) 0.353
Hypercholesterolemia5
Present (n = 33 MI, 50 C) 1.00 1.17 (0.65, 2.10) 1.43 (0.99, 2.11) 0.056
Not present (n = 27 MI, 62 C) 1.00 1.03 (0.56, 1.90) 1.17 (0.80, 1.74) 0.410
Diabetes
Present (n = 12 MI, 22 C) 1.00 3.35 (0.91, 19.92) 2.41 (1.12, 7.67) 0.027
Not present (n = 47 MI, 85 C) 1.00 0.95 (0.60, 1.49) 1.11 (0.81, 1.50) 0.541
1 Adjusted for age, sex, body mass index, pack-years of smoking, equivalent household income (5 categories), and alcohol intake (5 categories). C, control
subjects.
2 Reference category.
3 Adjusted for age, sex, body mass index, equivalent household income (5 categories), and alcohol intake (5 categories).
4 Defined as a systolic blood pressure >140 mm Hg, or a diastolic blood pressure >90 mm Hg, or use of antihypertensive medication.
5 Serum cholesterol > 6.5 mmol/L.
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dized LDL causes lipid accumulation in macrophages and foam
cell formation (31, 32) and has been shown to be cytotoxic to
many cell types and chemotactic for monocyte macrophages.
Lipid peroxidation of LDL can be enhanced by metal-catalyzed
reactions, resulting in highly reactive hydroxyl radicals. Superox-
ide anions produced by oxidative stress and reducing agents have
been found to be capable of mobilizing iron from ferritin (29, 30).
In the present study we observed dietary heme iron to be asso-
ciated with increased risk of myocardial infarction. Increased
risk of nonfatal myocardial infarction or fatal ischemic heart dis-
ease with heme iron intake was also reported in the Health Pro-
fessionals’ Study (33). Observations among Seventh-day Adven-
tists in whom meat consumption ‡ 6 times/wk was associated
with increased risk of fatal ischemic heart disease (34) are fur-
thermore supportive of a possible role of heme iron in ischemic
heart disease. Results suggestive of a role of heme iron in lipid
peroxidation also came from a nested, case-control study show-
ing a positive association between blood hemoglobin concentra-
tion and the titer of autoantibodies against malondialdehyde-
modified LDL (35) and from the ability of hemin to efficiently
promote LDL oxidation in vitro (36).
In conclusion, we observed elevated serum ferritin concentra-
tions to be associated with increased risk of myocardial infarction
in our elderly population. An increased risk was most evident in
current or former smokers and in subjects with diabetes, suggest-
ing that ferritin may adversely affect ischemic heart disease risk
in the presence of other risk factors. It may be possible that these
factors in interaction with elevated body iron stores may acceler-
ate atherogenesis by stimulating the oxidation of LDLs.
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